72 related articles for article (PubMed ID: 9360712)
1. Development and validation of AI/ML derived splice-switching oligonucleotides.
Fronk AD; Manzanares MA; Zheng P; Geier A; Anderson K; Stanton S; Zumrut H; Gera S; Munch R; Frederick V; Dhingra P; Arun G; Akerman M
Mol Syst Biol; 2024 Jun; 20(6):676-701. PubMed ID: 38664594
[TBL] [Abstract][Full Text] [Related]
2. Antisense-mediated redirection of mRNA splicing.
Vacek M; Sazani P; Kole R
Cell Mol Life Sci; 2003 May; 60(5):825-33. PubMed ID: 12827272
[TBL] [Abstract][Full Text] [Related]
3. Oligonucleotide⁻Palladacycle Conjugates as Splice-Correcting Agents.
Hande M; Saher O; Lundin KE; Smith CIE; Zain R; Lönnberg T
Molecules; 2019 Mar; 24(6):. PubMed ID: 30917503
[TBL] [Abstract][Full Text] [Related]
4. Targeting RNA splicing for disease therapy.
Havens MA; Duelli DM; Hastings ML
Wiley Interdiscip Rev RNA; 2013; 4(3):247-66. PubMed ID: 23512601
[TBL] [Abstract][Full Text] [Related]
5. Moonlighting functions of the ubiquitin-like protein, Hub1/UBL-5.
Kolathur KK; Mallya S; Barve S; Bojja SL; Wagle MM
Int J Biochem Cell Biol; 2023 Sep; 162():106445. PubMed ID: 37453225
[TBL] [Abstract][Full Text] [Related]
6. Creating a path to splice-switching ASO therapies.
Kingwell K
Nat Rev Drug Discov; 2023 Sep; 22(9):693. PubMed ID: 37528209
[No Abstract] [Full Text] [Related]
7. hnRNP L regulates the tumorigenic capacity of lung cancer xenografts in mice via caspase-9 pre-mRNA processing.
Goehe RW; Shultz JC; Murudkar C; Usanovic S; Lamour NF; Massey DH; Zhang L; Camidge DR; Shay JW; Minna JD; Chalfant CE
J Clin Invest; 2010 Nov; 120(11):3923-39. PubMed ID: 20972334
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of splice-switching oligonucleotides.
Bauman J; Jearawiriyapaisarn N; Kole R
Oligonucleotides; 2009 Mar; 19(1):1-13. PubMed ID: 19125639
[TBL] [Abstract][Full Text] [Related]
9. Making antisense of splicing.
Garcia-Blanco MA
Curr Opin Mol Ther; 2005 Oct; 7(5):476-82. PubMed ID: 16248283
[TBL] [Abstract][Full Text] [Related]
10. Splicing in the immune system: potential targets for therapeutic intervention by antisense-mediated alternative splicing.
Mourich DV; Iversen PL
Curr Opin Mol Ther; 2009 Apr; 11(2):124-32. PubMed ID: 19330718
[TBL] [Abstract][Full Text] [Related]
11. Modification of pre-mRNA splicing by antisense oligonucleotides.
Kole R
Acta Biochim Pol; 1997; 44(2):231-7. PubMed ID: 9360712
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of splicing of wild-type and mutated luciferase-adenovirus pre-mRNAs by antisense oligonucleotides.
Hodges D; Crooke ST
Mol Pharmacol; 1995 Nov; 48(5):905-18. PubMed ID: 7476922
[TBL] [Abstract][Full Text] [Related]
13. Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides.
Sierakowska H; Sambade MJ; Agrawal S; Kole R
Proc Natl Acad Sci U S A; 1996 Nov; 93(23):12840-4. PubMed ID: 8917506
[TBL] [Abstract][Full Text] [Related]
14. Correction of aberrant pre-mRNA splicing by antisense oligonucleotides in beta-thalassemia Egyptian patients with IVSI-110 mutation.
El-Beshlawy A; Mostafa A; Youssry I; Gabr H; Mansour IM; El-Tablawy M; Aziz M; Hussein IR
J Pediatr Hematol Oncol; 2008 Apr; 30(4):281-4. PubMed ID: 18391696
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of luciferase gene expression with antisense oligonucleotides: implications and applications in functional assay development.
Kang SH; Cho MJ; Kole R
Biochemistry; 1998 May; 37(18):6235-9. PubMed ID: 9572837
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
